ArticleNature communications2022
Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Humoral and cellular responses to SARS-CoV-2 variants after ancestral COVID-19 vaccines in people with HIV and lung transplant recipients.Clinical & translational immunology · 2026Article
- Respiratory viral infections in lung transplantation: Recent advances in epidemiology, clinical impact, and therapeutic approaches.JHLT open · 2025Article
- Differential immunity induced by Omicron sublineages in naïve and vaccine breakthrough infections.Scientific reports · 2025Article
- Nano Selenium: A Promising Solution for Infectious Diseases - Current Status and Future Prospects.Current pharmaceutical design · 2025Review
- Article
- Article
- Comparison of COVID-19 Hospitalization and Death Between Solid Organ Transplant Recipients and the General Population in Canada, 2020-2022.Transplantation direct · 2024Article
- Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada.Heliyon · 2024Article
- Clinical and prognostic implications of hyaluronic acid in patients with COVID-19 reinfection and first infection.Frontiers in microbiology · 2024Article
- COVID-19 Outcomes in Kidney Transplant Recipients in a German Transplant Center.Journal of clinical medicine · 2023Article
- Delayed and Attenuated Antibody Responses to Coronavirus Disease 2019 Vaccination With Poor Cross-Variant Neutralization in Solid-Organ Transplant Recipients-A Prospective Longitudinal Study.Open forum infectious diseases · 2023Article
- Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states.Science translational medicine · 2023Article
- Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations.Pharmaceutics · 2023Review
- Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
- Heterologous versus homologous boosting elicits qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients.JCI insight · 2023Article
- Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
- Inefficient Recovery of Repeatedly Stimulated Memory CD8 T Cells after Polymicrobial Sepsis Induction Leads to Changes in Memory CD8 T Cell Pool Composition.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations.Frontiers in cellular and infection microbiology · 2023Article
- Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunocompromised patients are predisposed to severe COVID-19. Here we compare homotypic and heterotypic humoral and cellular immune responses to Omicron BA.1 in organ transplant patients across a diverse clinical spectrum. We perform variant-specific pseudovirus neutralization assays for D614G, and Omicron-BA.1, -BA.2, and Delta variants. We also measure poly-and monofunctional T-cell responses to BA.1 and ancestral SARS-CoV-2 peptide pools. We identify that partially or fully-vaccinated transplant recipients after infection with Omicron BA.1 have the greatest BA.1 neutralizing antibody and BA.1-specific polyfunctional CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.